Subscribe to RSS
Does Antenatal Progesterone Administration Modify the Risk of Neonatal Intraventricular Hemorrhage?Funding None.
Objective Progesterone administration has been associated with improved neurological outcomes following traumatic brain injury in adults. However, studies examining the effect of progesterone on the risk of neonatal intraventricular hemorrhage (IVH) are inconsistent. We sought to determine if maternal administration of intramuscular 17-α-hydroxyprogesterone caproate (17-OHPC) is associated with decreased rates of IVH in infants born before 32-weeks gestation.
Study Design This is a retrospective study of liveborn singleton deliveries between 20- and 32-weeks gestation at two large academic medical centers from January 1, 2012 to August 30, 2020. Data were extracted from hospital electronic medical record data warehouses using standardized definitions and billing and diagnosis codes. We evaluated receipt of 17-OHPC in the antepartum period and diagnosis of IVH (grade I-IV, per Volpe classification) during the neonatal delivery hospitalization encounter. Bivariate and multivariate analyses were performed to examine the association between 17-OHPC and neonatal IVH adjusting for potential confounders. Odds ratio (ORs) and 95% confidence intervals (CIs) were presented.
Results Among 749 neonates born between 20- and 32-week gestation, 140 (18.7%) of their mothers had received antenatal 17-OHPC and 148 (19.8%) were diagnosed with IVH after birth. No significant association was observed between maternal 17-OHPC and neonatal IVH in unadjusted (OR 1.14, 95% CI 0.72–1.78) or adjusted analyses (adjusted odds ratio 1.14, 95% CI 0.71–1.84). Independent of exposure to 17-OHPC, as expected, infants born <28-weeks gestation or those with very low birthweight (<1,500 g) were at an increased risk of IVH (OR 2.32, 95% CI 1.55–3.48 and OR 2.19, 95% CI 1.09–4.38, respectively).
Conclusion Antenatal maternal 17-OHPC administration was not associated with the risk of neonatal IVH. Further research may be warranted to determine whether timing, route of delivery, and duration of progesterone therapy impact rates of neonatal IVH.
This study aimed to compare the frequency of intraventricular hemorrhage in preterm neonates exposed to antenatal 17-α-hydroxyprogesterone caproate to those not exposed.
In neonates born at <32-weeks gestation, maternal use of progesterone is not associated with the risk of intraventricular hemorrhage.
In contrast to preclinical and adult data, this study suggests that progesterone exposure is not associated with the prevention of neonatal brain injury.
Keywordsbetamethasone - intraventricular hemorrhage - magnesium sulfate - neonatal brain injury - gestational age - preterm birth - very low birthweight - 17-α-hydroxyprogesterone caproate
Received: 10 March 2022
Accepted: 05 April 2022
Accepted Manuscript online:
18 April 2022
Article published online:
10 June 2022
© 2022. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
- 1 Volpe J, Inder TE, Darras B. et al. Volpe's Neurology of the Newborn. 6th ed. Amsterdam, Netherlands: Elsevier; 2018
- 2 Volpe JJ. Brain injury in the premature infant: overview of clinical aspects, neuropathology, and pathogenesis. Semin Pediatr Neurol 1998; 5 (03) 135-151
- 3 Fanaroff AA, Stoll BJ, Wright LL. et al; NICHD Neonatal Research Network. Trends in neonatal morbidity and mortality for very low birthweight infants. Am J Obstet Gynecol 2007; 196 (02) 147.e1-147.e8
- 4 Hughes D, Murphy JF, Dyas J, Robinson JA, Riad-Fahmy D, Hughes IA. Blood spot glucocorticoid concentrations in ill preterm infants. Arch Dis Child 1987; 62 (10) 1014-1018
- 5 Dorner RA, Burton VJ, Allen MC, Robinson S, Soares BP. Preterm neuroimaging and neurodevelopmental outcome: a focus on intraventricular hemorrhage, post-hemorrhagic hydrocephalus, and associated brain injury. J Perinatol 2018; 38 (11) 1431-1443
- 6 Robinson S. Neonatal posthemorrhagic hydrocephalus from prematurity: pathophysiology and current treatment concepts. J Neurosurg Pediatr 2012; 9 (03) 242-258
- 7 Murphy SL, Mathews TJ, Martin JA, Minkovitz CS, Strobino DM. Annual Summary of Vital Statistics: 2013-2014. Pediatrics 2017; 139 (06) e20163239
- 8 Ballabh P. Pathogenesis and prevention of intraventricular hemorrhage. Clin Perinatol 2014; 41 (01) 47-67
- 9 Ballabh P, Braun A, Nedergaard M. The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis 2004; 16 (01) 1-13
- 10 Chevallier M, Debillon T, Pierrat V. et al; Neurodevelopment EPIPAGE 2 Writing Group. Leading causes of preterm delivery as risk factors for intraventricular hemorrhage in very preterm infants: results of the EPIPAGE 2 cohort study. Am J Obstet Gynecol 2017; 216 (05) 518.e1-518.e12
- 11 McGoldrick E, Stewart F, Parker R, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 2020; 12: CD004454
- 12 Shankaran S, Bauer CR, Bain R, Wright LL, Zachary J. The NICHD Neonatal Research Network. Relationship between antenatal steroid administration and grades III and IV intracranial hemorrhage in low birth weight infants. Am J Obstet Gynecol 1995; 173 (01) 305-312
- 13 Wright LL, Verter J, Younes N. et al. Antenatal corticosteroid administration and neonatal outcome in very low birth weight infants: the NICHD Neonatal Research Network. Am J Obstet Gynecol 1995; 173 (01) 269-274
- 14 Meis PJ, Klebanoff M, Thom E. et al; National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003; 348 (24) 2379-2385
- 15 EPPPIC Group. Evaluating Progestogens for Preventing Preterm birth International Collaborative (EPPPIC): meta-analysis of individual participant data from randomised controlled trials. Lancet 2021; 397 (10280): 1183-1194
- 16 Sanchez-Ramos L, Kaunitz AM, Delke I. Progestational agents to prevent preterm birth: a meta-analysis of randomized controlled trials. Obstet Gynecol 2005; 105 (02) 273-279
- 17 Briery CM, Klauser CK, Martin RW, Magann EF, Chauhan SP, Morrison JC. The use of 17-hydroxy progesterone in women with arrested preterm labor: a randomized clinical trial. J Matern Fetal Neonatal Med 2014; 27 (18) 1892-1896
- 18 Committee Opinion No 700: methods for estimating the due date. Obstet Gynecol 2017; 129 (05) e150-e154
- 19 Lemons JA, Bauer CR, Oh W. et al; NICHD Neonatal Research Network. Very low birth weight outcomes of the National Institute of Child health and human development neonatal research network, January 1995 through December 1996. Pediatrics 2001; 107 (01) E1
- 20 Tan AP, Svrckova P, Cowan F, Chong WK, Mankad K. Intracranial hemorrhage in neonates: a review of etiologies, patterns and predicted clinical outcomes. Eur J Paediatr Neurol 2018; 22 (04) 690-717
- 21 Levene MI, Fawer CL, Lamont RF. Risk factors in the development of intraventricular haemorrhage in the preterm neonate. Arch Dis Child 1982; 57 (06) 410-417
- 22 Sarkar S, Bhagat I, Dechert R, Schumacher RE, Donn SM. Severe intraventricular hemorrhage in preterm infants: comparison of risk factors and short-term neonatal morbidities between grade 3 and grade 4 intraventricular hemorrhage. Am J Perinatol 2009; 26 (06) 419-424
- 23 Stoll BJ, Hansen NI, Bell EF. et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. Pediatrics 2010; 126 (03) 443-456
- 24 Handley SC, Passarella M, Lee HC, Lorch SA. Incidence trends and risk factor variation in severe intraventricular hemorrhage across a population based cohort. J Pediatr 2018; 200: 24-29 .e3
- 25 Sotiriadis A, Papatheodorou S, Makrydimas G. Perinatal outcome in women treated with progesterone for the prevention of preterm birth: a meta-analysis. Ultrasound Obstet Gynecol 2012; 40 (03) 257-266
- 26 Guennoun R. Progesterone in the brain: hormone, neurosteroid and neuroprotectant. Int J Mol Sci 2020; 21 (15) E5271
- 27 Ishrat T, Sayeed I, Atif F, Hua F, Stein DG. Progesterone and allopregnanolone attenuate blood-brain barrier dysfunction following permanent focal ischemia by regulating the expression of matrix metalloproteinases. Exp Neurol 2010; 226 (01) 183-190
- 28 Won S, Lee JH, Wali B, Stein DG, Sayeed I. Progesterone attenuates hemorrhagic transformation after delayed tPA treatment in an experimental model of stroke in rats: involvement of the VEGF-MMP pathway. J Cereb Blood Flow Metab 2014; 34 (01) 72-80
- 29 Grossman KJ, Goss CW, Stein DG. Effects of progesterone on the inflammatory response to brain injury in the rat. Brain Res 2004; 1008 (01) 29-39
- 30 Yousuf S, Atif F, Sayeed I, Wang J, Stein DG. Neuroprotection by progesterone after transient cerebral ischemia in stroke-prone spontaneously hypertensive rats. Horm Behav 2016; 84: 29-40
- 31 Aggarwal R, Medhi B, Pathak A, Dhawan V, Chakrabarti A. Neuroprotective effect of progesterone on acute phase changes induced by partial global cerebral ischaemia in mice. J Pharm Pharmacol 2008; 60 (06) 731-737
- 32 Guennoun R, Zhu X, Fréchou M. et al. Steroids in stroke with special reference to progesterone. Cell Mol Neurobiol 2019; 39 (04) 551-568
- 33 Zhang Z, Yang R, Cai W, Bai Y, Sokabe M, Chen L. Treatment with progesterone after focal cerebral ischemia suppresses proliferation of progenitor cells but enhances survival of newborn neurons in adult male mice. Neuropharmacology 2010; 58 (06) 930-939
- 34 Begemann M, Leon M, van der Horn HJ, van der Naalt J, Sommer I. Drugs with anti-inflammatory effects to improve outcome of traumatic brain injury: a meta-analysis. Sci Rep 2020; 10 (01) 16179
- 35 Pan ZY, Zhao YH, Huang WH, Xiao ZZ, Li ZQ. Effect of progesterone administration on the prognosis of patients with severe traumatic brain injury: a meta-analysis of randomized clinical trials. Drug Des Devel Ther 2019; 13: 265-273
- 36 Xiao G, Wei J, Yan W, Wang W, Lu Z. Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Crit Care 2008; 12 (02) R61
- 37 De Nicola AF, Garay LI, Meyer M. et al. Neurosteroidogenesis and progesterone anti-inflammatory/neuroprotective effects. J Neuroendocrinol 2018; 30 (02) DOI: 10.1111/jne.12502.
- 38 Webster KM, Wright DK, Sun M. et al. Progesterone treatment reduces neuroinflammation, oxidative stress and brain damage and improves long-term outcomes in a rat model of repeated mild traumatic brain injury. J Neuroinflammation 2015; 12: 238
- 39 Roof RL, Hoffman SW, Stein DG. Progesterone protects against lipid peroxidation following traumatic brain injury in rats. Mol Chem Neuropathol 1997; 31 (01) 1-11
- 40 Irwin RW, Yao J, Hamilton RT, Cadenas E, Brinton RD, Nilsen J. Progesterone and estrogen regulate oxidative metabolism in brain mitochondria. Endocrinology 2008; 149 (06) 3167-3175
- 41 Céspedes Rubio ÁE, Pérez-Alvarez MJ, Lapuente Chala C, Wandosell F. Sex steroid hormones as neuroprotective elements in ischemia models. J Endocrinol 2018; 237 (02) R65-R81
- 42 Volpe JJ. Confusions in nomenclature: “periventricular leukomalacia” and “white matter injury”-identical, distinct, or overlapping?. Pediatr Neurol 2017; 73: 3-6
- 43 Parikh NA, He L, Li H, Priyanka Illapani VS, Klebanoff MA. Antecedents of objectively diagnosed diffuse white matter abnormality in very preterm infants. Pediatr Neurol 2020; 106: 56-62